<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36523407</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Severe acute infection and chronic pulmonary disease are risk factors for developing post-COVID-19 conditions.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2022.11.30.22282831</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2022.11.30.22282831</ELocationID><Abstract><AbstractText>Post-COVID-19 conditions, also known as "long COVID", has significantly impacted the lives of many individuals, but the risk factors for this condition are poorly understood. In this study, we performed a retrospective EHR analysis of 89,843 individuals at a multi-state health system in the United States with PCR-confirmed COVID-19, including 1,086 patients diagnosed with long COVID and 1,086 matched controls not diagnosed with long COVID. For these two cohorts, we evaluated a wide range of clinical covariates, including laboratory tests, medication orders, phenotypes recorded in the clinical notes, and outcomes. We found that chronic pulmonary disease (CPD) was significantly more common as a pre-existing condition for the long COVID cohort than the control cohort (odds ratio: 1.9, 95% CI: [1.5, 2.6]). Additionally, long-COVID patients were more likely to have a history of migraine (odds ratio: 2.2, 95% CI: [1.6, 3.1]) and fibromyalgia (odds ratio: 2.3, 95% CI: [1.3, 3.8]). During the acute infection phase, the following lab measurements were abnormal in the long COVID cohort: high triglycerides (mean<sub>longCOVID</sub>: 278.5 mg/dL vs. mean<sub>control</sub>: 141.4 mg/dL), low HDL cholesterol levels (mean<sub>longCOVID</sub>: 38.4 mg/dL vs. mean<sub>control</sub>: 52.5 mg/dL), and high neutrophil-lymphocyte ratio (mean<sub>longCOVID</sub>: 10.7 vs. mean<sub>control</sub>: 7.2). The hospitalization rate during the acute infection phase was also higher in the long COVID cohort compared to the control cohort (rate<sub>longCOVID</sub>: 5% vs. rate<sub>control</sub>: 1%). Overall, this study suggests that the severity of acute infection and a history of CPD, migraine, CFS, or fibromyalgia may be risk factors for long COVID symptoms. Our findings motivate clinical studies to evaluate whether suppressing acute disease severity proactively, especially in patients at high risk, can reduce incidence of long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Pritha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>nference Labs, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niesen</LastName><ForeName>Michiel J M</ForeName><Initials>MJM</Initials><AffiliationInfo><Affiliation>nference, inc., Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawlowski</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>nference, inc., Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandi</LastName><ForeName>Hari</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>nference, inc., Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Unice</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>nference, inc., Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenehan</LastName><ForeName>Patrick J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>nference, inc., Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M</LastName><ForeName>Praveen Kumar</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>nference Labs, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadig</LastName><ForeName>Mihika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>nference, inc., Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>nference, inc., 18 3rd St. S.W., Rochester MN 55902, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardhanari</LastName><ForeName>Sankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>nference, inc. 2424 Erwin Road, Durham, NC 27705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Horo</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatakrishnan</LastName><ForeName>A J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>nference, inc., Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Clifford J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Maine Medical Center, Portland, ME 04102, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIH RECOVER Initiative, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Telenti</LastName><ForeName>Amalio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vir Biotechnology, inc., San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurt</LastName><ForeName>Ryan T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soundararajan</LastName><ForeName>Venky</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>nference Labs, Bengaluru, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>nference, inc., Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>nference, inc., 18 3rd St. S.W., Rochester MN 55902, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>nference, inc. 2424 Erwin Road, Durham, NC 27705, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anumana, inc., Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>iScience. 2024 Jun 28;27(8):110406. doi: 10.1016/j.isci.2024.110406</RefSource><PMID Version="1">39081289</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>16</Day><Hour>2</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36523407</ArticleId><ArticleId IdType="pmc">PMC9753786</ArticleId><ArticleId IdType="doi">10.1101/2022.11.30.22282831</ArticleId><ArticleId IdType="pii">2022.11.30.22282831</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clarke K. E. N. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies &#x2014; United States, September 2021&#x2013;February 2022. MMWR Morb. Mortal. Wkly. Rep. 71, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098232</ArticleId><ArticleId IdType="pubmed">35482574</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. COVID Data Tracker. Centers for Disease Control and Prevention; 
https://covid.cdc.gov/covid-data-tracker (2020).</Citation></Reference><Reference><Citation>Tan B. K. J. et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ 378, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9326326</ArticleId><ArticleId IdType="pubmed">35896188</ArticleId></ArticleIdList></Reference><Reference><Citation>A clinical case definition of post COVID-19 condition by a Delphi consensus, 6
October
2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm#technical_notes (2022).</Citation></Reference><Reference><Citation>Subramanian A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 1&#x2013;9 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Laughlin K. N. et al. Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. PLoS One 17, e0264260 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893622</ArticleId><ArticleId IdType="pubmed">35239680</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVER: Researching COVID to Enhance Recovery. RECOVER: Researching COVID to Enhance Recovery
https://recovercovid.org/.</Citation></Reference><Reference><Citation>Murugadoss K. et al. Building a best-in-class automated de-identification tool for electronic health records through ensemble learning. Patterns (N Y) 2, 100255 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8212138</ArticleId><ArticleId IdType="pubmed">34179842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner T. et al. Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. Elife 9, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7410498</ArticleId><ArticleId IdType="pubmed">32633720</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatakrishnan A. J. et al. Mapping each pre-existing condition&#x2019;s association to short-term and long-term COVID-19 complications. NPJ Digit Med 4, 117 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316410</ArticleId><ArticleId IdType="pubmed">34315980</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurry R. et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med (N Y) 2, 965&#x2013;978.e5 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248717</ArticleId><ArticleId IdType="pubmed">34230920</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Long COVID or Post-COVID Conditions. Centers for Disease Control and Prevention; 
https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html (2022).</Citation></Reference><Reference><Citation>Charlson M. E., Pompei P., Ales K. L. &amp; MacKenzie C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373&#x2013;383 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff E. R. et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health 4, e532&#x2013;e541 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110014</ArticleId><ArticleId IdType="pubmed">35589549</ArticleId></ArticleIdList></Reference><Reference><Citation>Masana L. et al. Low HDL and high triglycerides predict COVID-19 severity. Sci. Rep. 11, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010012</ArticleId><ArticleId IdType="pubmed">33785815</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J. et al. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J. Med. Virol. 92, 2152 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273060</ArticleId><ArticleId IdType="pubmed">32406952</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C. et al. Hypoalbuminemia &#x2013; An Indicator of the Severity and Prognosis of COVID-19 Patients: A Multicentre Retrospective Analysis. Infect. Drug Resist. 14, 3699 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437137</ArticleId><ArticleId IdType="pubmed">34526790</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner J. et al. Elevated transaminases and hypoalbuminemia in Covid-19 are prognostic factors for disease severity. Sci. Rep. 11, 1&#x2013;5 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119433</ArticleId><ArticleId IdType="pubmed">33986318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S., Bae J. H., Kwon H.-S. &amp; Nauck M. A. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat. Rev. Endocrinol. 17, 11&#x2013;30 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7664589</ArticleId><ArticleId IdType="pubmed">33188364</ArticleId></ArticleIdList></Reference><Reference><Citation>Montefusco L. et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nature Metabolism 3, 774&#x2013;785 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931026</ArticleId><ArticleId IdType="pubmed">34035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett C. E. Risk for Newly Diagnosed Diabetes 30 Days After SARS-CoV-2 Infection Among Persons Aged 18 Years &#x2014; United States, March 1, 2020-June 28, 2021. MMWR Morb. Mortal. Wkly. Rep. 71, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757617</ArticleId><ArticleId IdType="pubmed">35025851</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer P. E., Kirwan J. P. &amp; Rosen C. J. Post-acute sequelae of COVID-19: A metabolic perspective. (2022) doi:10.7554/eLife.78200.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.78200</ArticleId><ArticleId IdType="pmc">PMC8942467</ArticleId><ArticleId IdType="pubmed">35318939</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiterer M. et al. Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab. 33, 2174 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8443335</ArticleId><ArticleId IdType="pubmed">34599884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xe9;nez-Col&#xf3;n G. J. et al. SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages. Sci. Transl. Med. (2022) doi:10.1126/scitranslmed.abm9151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abm9151</ArticleId><ArticleId IdType="pmc">PMC9529056</ArticleId><ArticleId IdType="pubmed">36137009</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Public Health Recommendations. Centers for Disease Control and Prevention; 
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-public-health-recs.html (2022).</Citation></Reference><Reference><Citation>Groenwold R. H. H. Informative missingness in electronic health record systems: the curse of knowing. Diagnostic and Prognostic Research 4, 1&#x2013;6 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371469</ArticleId><ArticleId IdType="pubmed">32699824</ArticleId></ArticleIdList></Reference><Reference><Citation>Tests and procedures. https://www.mayoclinic.org/tests-procedures (2020).</Citation></Reference><Reference><Citation>Test catalog - mayo clinic laboratories. https://www.mayocliniclabs.com/test-catalog.</Citation></Reference><Reference><Citation>Diagnostics &amp; Testing. Cleveland Clinic
https://my.clevelandclinic.org/health/diagnostics.</Citation></Reference><Reference><Citation>Medical Tests. ucsfhealth.org
https://www.ucsfhealth.org/medical-tests.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>